XENE Description — Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.

Company Name: 
Xenon Pharmaceuticals Inc
Number of ETFs Holding XENE: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   XENE Weight   XENE Amount 
 VHT   0.03%   $5,417,759         
 SPDW   0.02%   $2,997,597         
 ESML   0.07%   $900,529         
 BIB   0.15%   $143,392         
 SMLF   0.01%   $91,207         
 MMSC   0.91%   $46,100         
 IBBQ   0.20%   $26,225         
 PBSM   0.04%   $12,302         
Quotes delayed 20 minutes

Email EnvelopeFree XENE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (3.80 out of 4)
70th percentile
(ranked higher than approx. 70% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding XENE | Xenon Pharmaceuticals Inc | ETF Channel |

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.